Investors
News Releases
- June 18, 2024Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
- June 11, 2024Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
- June 5, 2024Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
- May 21, 2024Annovis Announces New Publication in a Peer-Reviewed Journal
- May 13, 2024Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
- May 9, 2024Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
- May 6, 2024Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
- April 29, 2024Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- April 2, 2024Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- April 1, 2024Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top